BR112022009522A2 - Métodos de administração de voxelotor - Google Patents

Métodos de administração de voxelotor

Info

Publication number
BR112022009522A2
BR112022009522A2 BR112022009522A BR112022009522A BR112022009522A2 BR 112022009522 A2 BR112022009522 A2 BR 112022009522A2 BR 112022009522 A BR112022009522 A BR 112022009522A BR 112022009522 A BR112022009522 A BR 112022009522A BR 112022009522 A2 BR112022009522 A2 BR 112022009522A2
Authority
BR
Brazil
Prior art keywords
voxelotor
methods
present
administration methods
cyp3a4
Prior art date
Application number
BR112022009522A
Other languages
English (en)
Inventor
B Washington Carla
Original Assignee
Global Blood Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Global Blood Therapeutics Inc filed Critical Global Blood Therapeutics Inc
Publication of BR112022009522A2 publication Critical patent/BR112022009522A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

MÉTODOS DE ADMINISTRAÇÃO DE VOXELOTOR. São fornecidos na presente invenção métodos para uso de voxelotor para o tratamento de doença falciforme em pacientes também tendo insuficiência hepática grave. Também são fornecidos na presente invenção métodos para administrar voxelotor e evitar ou diminuir interações de fármaco adversas com um indutor ou inibidor de CYP3A4. Também são fornecidos na presente invenção métodos para evitar interações com voxelotor, um inibidor moderado de CYP3A4.
BR112022009522A 2019-11-19 2020-11-17 Métodos de administração de voxelotor BR112022009522A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962937706P 2019-11-19 2019-11-19
US201962940154P 2019-11-25 2019-11-25
PCT/US2020/060923 WO2021101910A1 (en) 2019-11-19 2020-11-17 Methods of administering voxelotor

Publications (1)

Publication Number Publication Date
BR112022009522A2 true BR112022009522A2 (pt) 2022-08-16

Family

ID=73835728

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022009522A BR112022009522A2 (pt) 2019-11-19 2020-11-17 Métodos de administração de voxelotor

Country Status (7)

Country Link
US (1) US20230015823A1 (pt)
EP (1) EP4061368A1 (pt)
BR (1) BR112022009522A2 (pt)
CA (1) CA3161761A1 (pt)
IL (1) IL292982A (pt)
MX (1) MX2022006045A (pt)
WO (1) WO2021101910A1 (pt)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL312447A (en) * 2021-11-05 2024-06-01 Global Blood Therapeutics Inc Methods of treating sickle cell disease with Oxbryta

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2860323C (en) 2011-12-28 2022-03-08 The Regents Of The University Of California Substituted benzaldehyde compounds and methods for their use in increasing tissue oxygenation
MY189995A (en) 2014-02-07 2022-03-22 Global Blood Therapeutics Inc Crystalline polymorphs of the free base of 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde
MA43373A (fr) 2015-12-04 2018-10-10 Global Blood Therapeutics Inc Régimes posologiques pour 2-hydroxy-6-((2- (1-isopropyl-1h-pyrazol-5-yl)pyridin-3-yl)méthoxy)benzaldéhyde
TWI825524B (zh) 2016-05-12 2023-12-11 美商全球血液治療公司 用於合成2-羥基-6-((2-(1-異丙基-1h-吡唑-5-基)-吡啶-3-基)甲氧基)苯甲醛之方法
TW202332423A (zh) 2016-10-12 2023-08-16 美商全球血液治療公司 包含2-羥基-6-((2-(1-異丙基-1h-吡唑-5-基)吡啶-3-基)甲氧基)-苯甲醛之片劑

Also Published As

Publication number Publication date
IL292982A (en) 2022-07-01
CA3161761A1 (en) 2021-05-27
WO2021101910A1 (en) 2021-05-27
EP4061368A1 (en) 2022-09-28
US20230015823A1 (en) 2023-01-19
MX2022006045A (es) 2022-08-15

Similar Documents

Publication Publication Date Title
CY1124135T1 (el) Δοσολογικα σχηματα για την αγωγη της νοσου ρομρε
BR112015026006A2 (pt) métodos para o tratamento de câncer com o uso de terapia de combinação com inibidor de cinase tor
EA202092490A1 (ru) Модуляторы метилмодифицирующих ферментов, композиции и их применения
BR112018003985A2 (pt) macrociclos peptidomiméticos e usos dos mesmos
BRPI1011838B8 (pt) compostos de carboxamida heterocíclica de diamino, seu uso, composição farmacêutica que os compreende e inibidor contra a atividade de cinase de proteína de fusão eml4-alk
CY1118731T1 (el) Φαρμακευτικες συνθεσεις αλβιγλουτιδης
BR112015029512A2 (pt) derivados de pirazolopirrolidina e seu uso no tratamento de doenças
Benito-Cuesta et al. AMPK activation does not enhance autophagy in neurons in contrast to MTORC1 inhibition: different impact on β-amyloid clearance
BR112017024933A2 (pt) alvocidib produce com a bioavailabilidade aumentada
BR112015001419A2 (pt) composto, composição farmacêutica, e, métodos para inibir romk em um paciente, para causar diurese, natriurese ou ambos e para tratamento de um ou mais distúrbios
BR112016015818A2 (pt) Compostos e respectivos usos para tratar pacientes com células cancerosas mutantes em relação a ros1
CL2019003496A1 (es) Métodos de tratamiento de pacientes con enfermedad de fabry que tienen insuficiencia renal.
BRPI0622054B8 (pt) composto e composição farmacêutica
ATE535257T1 (de) Ophthalmologische formulierung mit methylsulfonylmethan und ciprofloxacin
BRPI0706676B8 (pt) uso de uma solução aquosa com potencial de oxirredução
AR089862A1 (es) USO DE LAQUINIMOD PARA EL TRATAMIENTO DE PACIENTES CON ENFERMEDAD DE CROHN EN QUIENES FRACASO UNA TERAPIA ANTI-FACTOR DE NECROSIS TUMORAL a (ANTI-TNFa) DE PRIMERA LINEA
MX2017000627A (es) Metodos para tratar pacientes con hipercolesterolemia familiar heterocigota (hfhe).
AR109103A1 (es) Tratamiento de la enfermedad de fabry en pacientes no tratados y tratados previamente con ert
AR096892A1 (es) Una combinación farmacéutica para el tratamiento del melanoma
BR112015026247A8 (pt) composto em combinação com um análogo de citidina, composição farmacêutica que os compreende, uso dos mesmos e kit
BR112013010829B8 (pt) Composição farmacêutica intravenosa para proporcionar alívio da dor e/ou da inflamação
BR112017007545A2 (pt) derivados de carbazol
CO2021008665A2 (es) Tratamiento de cefalea por uso excesivo de medicamentos usando anticuerpos anti-cgrp o anti-cgrp-r
CR20230100A (es) Compuestos fosfolípidos y usos de los mismos
BR112022000382A2 (pt) Administração de agonista de sting e inibidores de checkpoint